Genenta Science S.p.A.
GNTA$40M
Micro CapNASDAQBiological Products, (No Diagnostic Substances)🇺🇸North AmericaMILAN13 employees
Drugs in Pipeline
2
Phase 3 Programs
0
Upcoming Catalysts
1
Next Catalyst
Sep 2026
Market Overview
Stock performance and key metrics
GNTA News
Catalyst Timeline
1 upcoming, 0 past
Drug Pipeline
| Drug Name | Phase | Indication | Designations | Patent |
|---|---|---|---|---|
Pembrolizumab | Phase 2 | Clear Cell RCC | - | - |
Temferon | Phase 2 | Glioblastoma Multiforme | - | - |
Catalyst Verdict
Market-Implied Move
Regulatory Approvals
Get Catalyst Alerts
Receive weekly digests of upcoming catalysts
Data is aggregated from public sources (FDA, SEC, ClinicalTrials.gov). While we strive for accuracy, information may be incomplete, delayed, or contain errors. Terms apply